儿科药学杂志2025，Vol.31Issue(2)：26-31,6.DOI:10.13407/j.cnki.jpp.1672-108X.2025.02.006
基于失效模式和效应分析优化静脉用药调配中心鞘注液调配流程
Optimization of Dispensing Process for Intrathecal Injection in Pharmacy Intravenous Admixture Services Based on Failure Mode and Effects Analysis
摘要
Abstract
Objective:To analyze the quality control system in the dispensing process of Pharmacy Intravenous Admixture Services(PIVAS),optimize the dispensing process of intrathecal injection and improve the medication safety of patients.Methods:Failure mode and effects analysis(FMEA)was used to evaluate the risk points in the dispensing process of PIVAS and select the failure modes of medium and high risk levels.The causes of failure were analyzed to develop corresponding improvement measures,and the effectiveness of quality control was evaluated.Results:A total of 34 medium and high risk points were identified in the dispensing process for intrathecal injection in PIVAS,and improvements were made in personnel training,process improvement,quality control and inspection supervision.After 6 months of improvement for 34 medium and high risk points,the average risk priority number(RPN)decreased by 57.9％,the compliance rate of hand hygiene in pharmacists were improved,the compatibility rate of intrathecal injection increased from 96.3％before improvement to 97.7％after improvement,and the number of outdated medical orders decreased from(13.7±2.3)pieces per month to(8.2±1.3)pieces per month,with a decrease of 40.1％.Conclusion:The quality control risk points of intrathecal injection in the dispensing process of PIVAS can be identified and evaluated by FMEA.The quality control system in the dispensing process for intrathecal injection can timely identify medium and high risk points in the process,improve the medication safety in patients.关键词
失效模式和效应分析/静脉用药调配中心/鞘注液/质量控制体系Key words
failure mode and effects analysis/pharmacy intravenous admixture service/intrathecal injection/quality control system分类
医药卫生引用本文复制引用
陶柏成,王梅,刘杨,张先明,周丽芳,袁树伟..基于失效模式和效应分析优化静脉用药调配中心鞘注液调配流程[J].儿科药学杂志,2025,31(2):26-31,6.基金项目
江苏省药学会-正大天晴医院药学科研基金项目,编号Q202234. （）
